Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Cutting our fair value on ASX share after poor guidance
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,861.60 | 39.70 | -0.45% |
| CAC 40 | 8,052.51 | 55.92 | -0.69% |
| DAX 40 | 24,162.65 | 116.64 | 0.49% |
| Dow JONES (US) | 47,560.29 | 179.03 | -0.38% |
| FTSE 100 | 9,642.01 | 3.08 | -0.03% |
| HKSE | 25,331.09 | 103.14 | -0.41% |
| NASDAQ | 23,576.49 | 30.58 | 0.13% |
| Nikkei 225 | 50,461.55 | 193.55 | -0.38% |
| NZX 50 Index | 13,373.62 | 81.16 | -0.60% |
| S&P 500 | 6,840.51 | 6.00 | -0.09% |
| S&P/ASX 200 | 8,574.60 | 36.50 | -0.42% |
| SSE Composite Index | 3,881.51 | 28.01 | -0.72% |